Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 283 - 310 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194781405&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 194781405 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2026 Supplement 19 vid: 44 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 194781405 10.1200/JCO.2026.44.19_suppl.283 194781405 ppf: 283 ppct: 27 formats: tig: atl: Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis. aug: au: Biswas, Shankar Srivastava, Yashasvi Falodia, Rahul Hamadttu, Ayman affil: Sharda Hospital, Greater Noida, India sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|